Clinical Trial Update: Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)

View source ↗

Summary

Pfizer completed a special post-marketing trial of intravenous azithromycin for Legionnaires' disease. The results were posted on 2017-11-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Legionellosis
• Legionnaires Disease

Drugs mentioned

• Azithromycin (intravenous) (Azithromycin)

Snippet

Sponsor: Pfizer | Conditions: Legionnaires' Disease, Legionella Pneumophila Infections | Status: COMPLETED | Results posted: 2017-11-30